1. Clinical & Scientific Overview
Ibrutinib (TIP-MED-000572, Reference Code [ONC-23]) is classified under
Oncology & Antineoplastic Medicines as a Targeted Therapy (BTK Inhibitor) • First-in-Class Irreversible Bruton's Tyrosine Kinase (BTK) Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Imbruvica (Janssen / Johnson & Johnson), Ibrukast (BDR / Aprazer), Ibrutix (Natco Pharma)
Hard Capsule / Tablet: 140 mg
Oncology Specialisation & Cytotoxic Safety Protocol
Targeted Therapy (BTK Inhibitor)
Antineoplastic Targeted Agent
Standard Regimen & Cycle Context: CLL / WM: 420 mg orally once daily; Mantle Cell Lymphoma: 560 mg orally once daily.
Signature Dose-Limiting Toxicities & Organ Monitoring: Atrial Fibrillation and ventricular arrhythmias (off-target TEC and CSK kinase inhibition), major haemorrhage/bleeding (off-target platelet collagen GPVI signalling blockade via BTK/TEC), hypertension, and opportunistic infections; metabolised extensively by CYP3A4 (avoid grapefruit, Seville oranges, and strong azole antifungals).
Extravasation, Premedication & Safe Cytotoxic Handling: Reassure patients and clinicians that early asymptomatic rise in peripheral absolute lymphocyte count (redistribution lymphocytosis peaking at 4–8 weeks) is an expected pharmacodynamic effect and NOT disease progression; hold Ibrutinib for 3 to 7 days before and after minor/major surgical procedures due to platelet dysfunction.
3. Mechanism of Action & Pharmacodynamics
Forms a covalent bond with Cysteine-481 (Cys481) in the active site of Bruton's tyrosine kinase (BTK), blocking B-cell antigen receptor (BCR) and chemokine signalling, which forces malignant B-cells out of protective lymph node microenvironments into peripheral blood (causing transient redistribution lymphocytosis) followed by apoptosis.
4. Therapeutic Indications & Evidence-Supported Uses
- Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)
- Mantle Cell Lymphoma (MCL), Waldenstrom Macroglobulinaemia, and Chronic Graft-versus-Host Disease
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): CLL / WM: 420 mg orally once daily; Mantle Cell Lymphoma: 560 mg orally once daily.
Administration & Meal Timing: CLL / WM: 420 mg orally once daily; Mantle Cell Lymphoma: 560 mg orally once daily.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Ibrutinib or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Atrial Fibrillation and ventricular arrhythmias (off-target TEC and CSK kinase inhibition), major haemorrhage/bleeding (off-target platelet collagen GPVI signalling blockade via BTK/TEC), hypertension, and opportunistic infections; metabolised extensively by CYP3A4 (avoid grapefruit, Seville oranges, and strong azole antifungals).
8. Adverse Effects Profile
- Atrial Fibrillation and ventricular arrhythmias (off-target TEC and CSK kinase inhibition), major haemorrhage/bleeding (off-target platelet collagen GPVI signalling blockade via BTK/TEC), hypertension, and opportunistic infections; metabolised extensively by CYP3A4 (avoid grapefruit, Seville oranges, and strong azole antifungals).
- Atrial Fibrillation and ventricular arrhythmias (off-target TEC and CSK kinase inhibition), major haemorrhage/bleeding (off-target platelet collagen GPVI signalling blockade via BTK/TEC), hypertension, and opportunistic infections; metabolised extensively by CYP3A4 (avoid grapefruit, Seville oranges, and strong azole antifungals).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Atrial Fibrillation and ventricular arrhythmias (off-target TEC and CSK kinase inhibition), major haemorrhage/bleeding (off-target platelet collagen GPVI signalling blockade via BTK/TEC), hypertension, and opportunistic infections; metabolised extensively by CYP3A4 (avoid grapefruit, Seville oranges, and strong azole antifungals).
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Reassure patients and clinicians that early asymptomatic rise in peripheral absolute lymphocyte count (redistribution lymphocytosis peaking at 4–8 weeks) is an expected pharmacodynamic effect and NOT disease progression; hold Ibrutinib for 3 to 7 days before and after minor/major surgical procedures due to platelet dysfunction.
Pharmacist Patient Counselling Points:
- Reassure patients and clinicians that early asymptomatic rise in peripheral absolute lymphocyte count (redistribution lymphocytosis peaking at 4–8 weeks) is an expected pharmacodynamic effect and NOT disease progression; hold Ibrutinib for 3 to 7 days before and after minor/major surgical procedures due to platelet dysfunction.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Reassure patients and clinicians that early asymptomatic rise in peripheral absolute lymphocyte count (redistribution lymphocytosis peaking at 4–8 weeks) is an expected pharmacodynamic effect and NOT disease progression; hold Ibrutinib for 3 to 7 days before and after minor/major surgical procedures due to platelet dysfunction.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-22] Lenvatinib Mesylate — Targeted Therapy (Multi-Kinase Anti-Angiogenic TKI) • Multi-Targe
- [ONC-24] Palbociclib — Targeted Therapy (CDK4/6 Cell-Cycle Inhibitor) • Reversible Selec
- [ONC-25] Bortezomib — Targeted Therapy (Proteasome Inhibitor) • Reversible Dipeptidyl B
- [ONC-26] Rituximab — Monoclonal Antibody (Anti-CD20 Biologic) • Chimeric Murine/Human
